Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Tanzania has been witnessing a steady growth in recent years.
Customer preferences: Customers in Tanzania prefer generic immunosuppressants due to their affordability as compared to branded ones. The majority of the population in Tanzania cannot afford expensive branded drugs, and hence, the demand for generic drugs has been increasing. The government has also been promoting the use of generic drugs to reduce the burden of healthcare expenses on the population.
Trends in the market: The market for immunosuppressants in Tanzania has been witnessing a trend of increasing demand due to the rising prevalence of autoimmune diseases and organ transplantations. The increasing number of kidney transplants in the country has been driving the demand for immunosuppressants. Moreover, the government has been taking initiatives to improve the healthcare infrastructure in the country, which has been further fueling the growth of the immunosuppressants market.
Local special circumstances: Tanzania has a high burden of infectious diseases such as malaria, HIV/AIDS, and tuberculosis. These diseases weaken the immune system of the patients, which increases the risk of autoimmune diseases. The prevalence of autoimmune diseases in the country has been increasing, which has been driving the demand for immunosuppressants. Additionally, the country has a shortage of healthcare professionals, which has been a major challenge in the effective management of autoimmune diseases.
Underlying macroeconomic factors: The Tanzanian economy has been growing at a steady pace, which has been positively impacting the healthcare sector. The government has been investing in the healthcare infrastructure of the country, which has been improving the access to healthcare services. Moreover, the increasing disposable income of the population has been driving the demand for healthcare services, including immunosuppressants. However, the country still faces challenges such as poor healthcare facilities in rural areas, lack of healthcare professionals, and inadequate healthcare financing.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
